07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

Ceronco Biosciences preclinical data

In a mouse model of breast cancer, CB001 significantly improved overall survival (OS) vs. controls (30 vs. 11 days, p<0.005). CB001 also significantly increased intracellular tumor accumulation of doxorubicin by 1.9-fold vs. doxorubicin alone (p<0.05)....
07:00 , Apr 16, 2012 |  BioCentury  |  Emerging Company Profile

Ceronco: Gateway into the cell

Ceronco BioSciences B.V. is developing a short chain sphingolipid delivery technology that preferentially increases the uptake of chemotherapeutics into cancer cells, which could improve efficacy without increasing toxicity. CEO Jeroen Rovers said many formulation technologies, including...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

CB001: Development discontinued

VIAC said it will discontinue development of CB001 after data from an open-label, U.S. Phase I/II trial in 10 patients showed no chimerism by days 21-28. VIAC said that chimerism, the presence of donor cells,...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Clinical News

Hematopoietic stem cells: Preliminary Phase I/II data

Preliminary data from an open-label, U.S. Phase I/II trial in 10 patients showed no infusion toxicity events related to CB001. Patients will continue to be followed for 100 days post-transplant. FDA had lifted a clinical...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Clinical News

Hematopoietic stem cells: Phase I ongoing

FDA lifted its clinical hold on a Phase I trial. The trial was stopped after 2 cases of grade IV acute graft-versus-host disease (GVHD) were seen in 8 patients treated with CB001 (see BioCentury, Sept....
07:00 , Sep 26, 2005 |  BC Week In Review  |  Clinical News

Hematopoietic stem cells: Phase I suspended enrollment

VIAC suspended enrollment in a Phase I trial of CB001 for use in hematopoietic stem cell transplantation to treat cancer. The trial was stopped after 2 cases of grade IV acute graft-versus-host-disease (GVHD) were seen...
07:00 , Sep 26, 2005 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/23 cls Alnylam (ALNY) ThinkEquity Andrew McDonald Downgrade Accumulate (from buy) 14% $11.55 McDonald downgraded the stock because he believes the shares are "approaching...
07:00 , Sep 26, 2005 |  BioCentury  |  Finance

Ebb & Flow

Although Celtic Pharma originally planned to raise $1 billion for its structured product development fund, the firm's faster than expected pace of deals has prompted it to reconsider and scale back its appetite for funds....
23:53 , Sep 19, 2005 |  BC Extra  |  Clinical News

ViaCell falls on Phase I suspension

Cord blood company VIAC fell $1.39 (22%) to $5.05 on Monday on 2.6 million shares after it suspended enrollment in a Phase I trial of CB001 for use in hematopoietic stem cell transplantation to treat...
07:00 , May 16, 2005 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/13 cls ArQule (ARQL) America's Growth Capital David Wood New NA 7% $6.28 Wood expects data at ASCO from a Phase I trial of...